The digital health and wellbeing learning centre has become a trusted place where staff and volunteers can help people to improve their digital skills.
News
AZ, Transgene to collaborate on immunotherapies
The French biotech company will help AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates.
Nabriva hit with FDA rejection of Contempo for complicated urinary tract infections
The company cited issues related to facility inspections and manufacturing deficiencies at one contract manufacturer.
NICE recommends Roche’s Tecentriq for metastatic NSCLC
The recommendation is for the drug in combination with Avastin (bevacizumab), carboplatin and paclitaxel.
PharmaTimes Marketer of the Year Chair, Sabina Syed, reveals the benefits of entering in 2019
The PharmaTimes Marketer of the Year competition has been designed to help improve the standard of healthcare marketers throughout the industry via a unique process.
GSK makes “strong start” to year, as HIV and shingles meds boost Q1 sales
The results showed revenue growth across all three of GSK’s divisions.
UK & Irish experts urge for different approach to Psoriatic Arthritis management
The new educational campaign is called ‘Six Domains: One Disease‘.
US approves first all-genotype treatment for pediatric hepatitis C
AbbVie’s Mavyret treats all six genotypes of hepatitis C virus.
FDA pushes for stronger warnings on insomnia medicines
The change comes after reports of rare but serious injuries and deaths resulting from various complex sleep behaviours.
“Prevention more important than cure”, say MPs on NHS
49% of MPs said that they are confident that the NHS Long Term Plan will be successful in improving the prevention of ill health and disease.
New NICE guideline to help spot suspected neurological conditions
The guideline covers symptoms and signs that should prompt a referral for further neurological assessment.
AZ announces Phase I DS-8201 results
Approximately one in five breast and gastric cancers are HER2-positive.
ViiV submits NDA for first long-acting, injectable HIV combo
The combination of cabotegravir and Edurant has the potential to give people living with HIV one month between doses.
European approval for AbbVie’s Skyrizi
The approval is for the treatment of moderate to severe plaque psoriasis.
Tech could help boost adult vaccination rates
The report highlights the danger of the growing anti-vaccination sentiment.
